Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Participants With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy

Inclusion Criteria:

participants or their legal representative must have signed an informed consent document for clinical research
have laboratory confirmed diagnosis of advanced, nonsquamous cell non-small cell lung cancer (NSCLC) (Stage IIIB or IV disease) which is not curable
have not received any prior systemic chemotherapy, immunotherapy, targeted therapy, or biological therapy for advanced NSCLC, prior radiation therapy is allowed to less than 25% of the bone marrow
have measurable disease
have adequate organ function and estimated life expectancy of 12 weeks

Exclusion Criteria:

have known central nervous system (CNS) disease; major surgery within 28 days; minor surgery within 7 days; serious concomitant systemic disorder; serious cardiac condition; have a serious, nonhealing wound, ulcer, or bone fracture
have received treatment within the last 30 days with any drug that has not received regulatory approval for any indication at the time of study entry
have previously received treatment with enzastaurin, pemetrexed, or bevacizumab
are pregnant or breast-feeding
are unable to swallow tablets